ArticleCancer science2022

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan.

Takayuki Ikezoe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.